In this installment of Psychedelica Lex, I interview fellow psychedelic attorney Matthew Brockmeier. Matthew works with Emerge, one of the larger national law firms focusing on psychedelic law. Matthew is based in Denver, Colorado and […]
In this installment of Psychedelica Lex, I interview Sully Sullivan regarding the Hemp Industry Trade Association’s (HITA) SB1271 – Arizona’s Hemp-Derived Products (HDP) Safety & Regulation Bill.
You can watch the episode HERE.
Per […]
In January a bipartisan bill proposing to allocate $30,000,000 to research psilocybin (and not just the chemical, but the whole mushroom!) was introduced in the Arizona House.
Come see House Bill 2486 and hear the […]
In this installment of Psychedelica Lex, I introduce my free online psychedelic law library.
I mentioned throughout 2022 that I would be getting the library posted. Well, it took me until the winter holiday to find […]
Back from Miami, reinvigorated and more encouraged than ever. Thank you Cannadelic for hosting me and my esteemed co-presenter, Greg Lake, Esq.
This year, Greg and I gave glimpses inside some of the major […]
Entheogen attorney Danni Peterson returns to Psychedelica Lex to share his latest news, victory for psychedelic religion in Colorado, and separately the work and progress of the Ass’n of Entheogenic Practitioners that […]
In this latest installment of Psychedelica Lex, I share a seminar I gave in December 2022. The State Bar of Arizona was gracious once more to host the Arizona Cannabis Bar Association for its annual […]
This installment of Psychedelica Lex is another video letter to the Psychedelic Bar Association – Law and Regulatory Committee (LARC). This letter picks up where I left off in my last video letter to […]
In this installment of Psychedelica Lex, I present a video letter to the Psychedelic Bar Association’s Law and Regulatory Committee (LARC).
My topic is consideration of employing gatekeepers in the form of licensing users, as one […]
Well, the long-awaited final action letter from DEA has arrived. AIMS Institute is now clear to pursue its claims against DEA to stop DEA from interdicting use of Phase II experimental psilocybin compounds on […]
